Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 15/20 | 0.70 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.70 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | BLM | P54132 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | SPR | P35270 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5346043 | 0.85 | MTNR1A (0.71) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL14960976 | 0.85 | MTNR1A (0.71) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL5346251 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL5341347 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL5338813 | 0.83 | SPR (0.58) | MTNR1AMTNR1BCYP1A2MEN1KMT2A | |
| SCHEMBL14962811 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL8142211 | 0.80 | MTNR1A (0.66) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL31252456 | 0.78 | MTNR1A (0.75) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL5336251 | 0.77 | MTNR1A (0.62) | MTNR1AMTNR1BNOTUMCYP1A2BLM | |
| SCHEMBL6763965 | 0.75 | MTNR1A (0.74) | MTNR1AMTNR1BNOTUMCYP1A2BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183318-B2 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2007-02-27 | — | — | US | disclosed |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | LESIEUR DANIEL (FR) | 2004-01-01 | — | — | US | disclosed |
| US-6605632-B1 | Affinity for melatonin receptors | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002491-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP4B1, CYP3A5, MC2R | MTNR1A 388/4885MTNR1B 325/4885NOTUM 1748/4885 |
| US-20040002490-A1 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them | CYP3A5, CYP4B1, MC2R | MTNR1A 409/4885MTNR1B 340/4885NOTUM 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.